Capital Markets Day: Commercial Execution and Innovation in Obesity Care
Commercial
execution
3
Commercial execution and innovation
Obesity care
Strategic aspirations 2025
Purpose and
Sustainability
(ESG)
Progress towards zero environmental impact
Being respected for adding value to society
Being recognised as a sustainable employer
Strengthen Diabetes leadership - aim at global value
market share of more than 1/3
Strengthen Obesity leadership and double current
sales¹
Secure a sustained growth outlook for Rare disease
Financials
Innovation and
therapeutic focus
•
•
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
1 Based on reported sales in 2019, 2 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Deliver solid sales and operating profit growth
Deliver 6-10% sales growth in IO
• Transform 70% of sales in the US²
Drive operational efficiencies across the value chain to
enable investments in future growth assets
Deliver free cash flow to enable attractive capital
allocation to shareholders
CMD22
CAPITAL MARKETS DAY
Novo NordiskⓇView entire presentation